← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Consegna Pharma, Inc.
Pittsburgh, PA
$3,177,692
Total funding
3
Grants
Funding over time
peak $1.7M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,177,692 · 3
By mechanism
R44$2,545,988 · 1
R43$326,500 · 1
R41$305,204 · 1
Investigators at Consegna Pharma, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
IND-enabling development of a long-duration antagonist to treat opioid overdose$1,330,781
R44 · FY2023 · DA
IND-enabling development of a long-duration antagonist to treat opioid overdose$837,364
R44 · FY2024 · DA
IND-enabling development of a long-duration antagonist to treat opioid overdose$377,843
R44 · FY2025 · DA
Long-acting injectable ketamine for improved substance use disorder (SUD) treatment without dissociative effects.$326,500
R43 · FY2023 · DA
Prevention of renarcotization from synthetic opioids$217,970
R41 · FY2019 · DA
Prevention of renarcotization from synthetic opioids$87,234
R41 · FY2020 · DA